sofidexFor patientsAre you a clinician? Clinical site

Meds & supplements  ›  Glasdegib

Medicine · Hedgehog Pathway Inhibitor

Glasdegib

DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction…

Medication guideLabel updated 2025-12-12

Selected manufacturer label information, organised into consistent sections by Sofidex. Read the full label at DailyMed ↗

Boxed warning

WARNING: EMBRYO-FETAL TOXICITY DAURISMO can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. DAURISMO is embryotoxic, fetotoxic, and teratogenic in animals. Conduct pregnancy testing in females of reproductive potential prior to initiation of DAURISMO treatment. Advise females of reproductive potential to use effective contraception during treatment with DAURISMO and for at least 30 days after the last dose. Advise males of the potential risk of DAURISMO exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with DAURISMO and for at least 30 days after the last dose to avoid potential drug exposure. WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. • DAURISMO can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. • Advise males of the potential risk of exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with DAURISMO and for at least 30 days after the last dose to avoid potential drug exposure.

Drug facts

Used for
DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction…
How to take it
Take DAURISMO with the medicine cytarabine exactly as your healthcare provider tells you.

What it is used for

DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. DAURISMO is a hedgehog pathway inhibitor indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.

The most important thing to know

DAURISMO can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects. For females who can become pregnant: You should talk to your healthcare provider about the risks of DAURISMO to your unborn child. Your healthcare provider will do a pregnancy test within 7 days before you start taking DAURISMO.

You should not use DAURISMO during pregnancy. You should use effective birth control during treatment and for at least 30 days after your last dose of DAURISMO. Talk with your healthcare provider about what birth control method is right for you during this time. Talk to your healthcare provider right away if you have unprotected sex or if you think that your birth control has failed.

Tell your healthcare provider right away if you become pregnant or think that you may be pregnant. For males: It is not known if DAURISMO is present in semen. Do not donate semen during treatment with DAURISMO and for at least 30 days after your last dose. You should always use effective birth control, including a condom, even if you have had a vasectomy, during sex with female partners who are pregnant or who are able to become pregnant, during treatment with DAURISMO and for at least 30 days after your last dose to protect your female partner from being exposed to DAURISMO.

Tell your healthcare provider right away if your partner becomes pregnant or thinks she is pregnant while you are taking DAURISMO. Exposure to DAURISMO during pregnancy: If you think that you or your female partner may have been exposed to DAURISMO during pregnancy, talk to your healthcare provider right away. If you become pregnant during treatment with DAURISMO, you or your healthcare provider should report your pregnancy to Pfizer at 1-800-438-1985.

What is DAURISMO? DAURISMO is a prescription medicine that is used with the medicine cytarabine to treat newly-diagnosed acute myeloid leukemia (AML) in adults who: are 75 years of age or older, or have other medical conditions that prevent the use of standard chemotherapy. It is not known if DAURISMO is safe and effective in children.

Before you take DAURISMO, tell your healthcare provider about all of your medical conditions, including if you: have heart problems, including a condition called long QT syndrome. abnormal blood salt (electrolytes) levels. have muscle pain or spasms. have kidney problems. are pregnant or plan to become pregnant. are breastfeeding or plan to breastfeed.

It is not known if DAURISMO passes into your breast milk. Do not breastfeed or provide breast milk to infants or children during treatment with DAURISMO and for at least 30 days after the last dose. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.

How to take it

Take DAURISMO with the medicine cytarabine exactly as your healthcare provider tells you. Take DAURISMO 1 time each day, at about the same time each day. Take DAURISMO with or without food. Do not chew, split or crush DAURISMO tablets. If you miss a dose of DAURISMO, take it as soon as you remember. If it is less than 12 hours before your next dose, just skip the missed dose and take your next dose at your regular time.

Side effects, and when to stop

DAURISMO can cause serious side effects, including: Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening. Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or feel your heart beating irregularly or fast during treatment with DAURISMO.

Muscle Problems. Muscle problems are common with DAURISMO, but can also sometimes be serious. DAURISMO can increase your risk of muscle pain or muscle spasms. Tell your healthcare provider right away if you develop any new or worsening muscle spasms, pain, tenderness or weakness during and after treatment with DAURISMO.

Your healthcare provider should do a blood test to check for muscle problems and to check your kidney function before you start taking DAURISMO, during treatment, and if you develop muscle problems. The most common side effects of DAURISMO with cytarabine include: low red blood cell count (anemia) tiredness bleeding fever with low white blood cell count muscle pain swelling of arms or legs low platelet count nausea shortness of breath decreased appetite changes in taste pain or sores in your mouth or throat constipation rash DAURISMO may affect fertility in males.

Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of DAURISMO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Who should not take it

Do not take 2 doses of DAURISMO within 12 hours. If you vomit after taking a dose of DAURISMO, do not take an extra dose, just take your next dose at your regular time. Your healthcare provider will perform certain tests to check you for side effects before and during treatment with DAURISMO. Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with DAURISMO if you have certain side effects.

Do not change your dose or stop taking DAURISMO unless your healthcare provider tells you. If you take too much DAURISMO, call your healthcare provider or go to the nearest hospital emergency room right away.

What to avoid

Do not donate blood or blood products during treatment with DAURISMO and for at least 30 days after the last dose. Do not donate semen during treatment with DAURISMO and for at least 30 days after the last dose.

Storing it

Store DAURISMO at room temperature between 68°F to 77°F (20°C to 25°C). Keep DAURISMO and all medicines out of the reach of children.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Glasdegib; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/glasdegib

APA 7th

sofidex. (2026, August 2). Glasdegib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/glasdegib

AMA 11th

Glasdegib. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/glasdegib

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.